NovalGen

Clinical-stage biotechnology company advancing breakthrough multi-specific biologics to transform outcomes in oncology, autoimmune, haematological, and metabolic disorders.

NovalGen is a clinical-stage biotechnology company advancing breakthrough multi-specific biologics to transform outcomes in oncology, autoimmune, haematological, and metabolic disorders. 

Their dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated bispecific antibody products tailored to the needs of the patient, enabling life-enhancing treatments for people with haematologic and solid tumours. 

The company’s lead program, NVG-222, is an ROR1-targeting bispecific antibody T-cell engager using their breakthrough bispecific and Autoregulation technology targeting liquid and solid tumors.

The NovalGen journey so far:

  • 2019: spinout founded 
  • 2026: Cancer Research UK and NovalGen dose the first patient in the Phase 1 trial of T-cell engager NVG-222
Dr Rick Fagan

Dr. Rick Fagan

Director of BioPharm

Institute of Clinical Trials and Methodology

Dr. Fagan brings extensive cell biology, pharma and technology transfer leadership experience, including AstraZeneca, SanofiAventis and UCL Ventures. He holds a PhD from McGill University.